Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
degs decrease » mean decrease (Expand Search), we decrease (Expand Search), deaths decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
based case » base case (Expand Search), based cancer (Expand Search)
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
degs decrease » mean decrease (Expand Search), we decrease (Expand Search), deaths decreased (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
based case » base case (Expand Search), based cancer (Expand Search)
-
61
-
62
-
63
-
64
Deterministic result of the base-case analysis.
Published 2024“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”
-
65
-
66
-
67
-
68
-
69
-
70
The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER.
Published 2025“…PS decreased TEER. (C) Different treatments (treatment groups n = 8)with HA and/or CS did not affect TEER recovery after PS treatment, full recovery was seen in all groups after 24 hours. …”
-
71
-
72
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
73
-
74
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
75
-
76
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
-
77
Base-case analysis.
Published 2023“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
-
78
-
79
-
80